OPKO Health (OPK) Financials

$1.42 +0.03 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 0.00 (-0.28%)

As of 04:14 PM Eastern

Annual Income Statements for OPKO Health

This table shows OPKO Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-172	-30	-48	-305	-153	-315	31	-30	-328	-189	-53
Consolidated Net Income / (Loss)	-175	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53
Net Income / (Loss) Continuing Operations	-175	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53
Total Pre-Tax Income	-171	-138	-97	-272	-177	-305	49	-14	-392	-184	-10
Total Operating Income	-146	-98	-97	-276	-171	-274	58	19	-226	-157	-152
Total Gross Profit	43	256	506	1,129	386	329	541	582	288	318	219
Total Revenue	91	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713
Operating Revenue	91	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713
Total Cost of Revenue	48	235	611	620	605	572	894	1,193	716	545	495
Operating Cost of Revenue	48	235	611	620	605	572	894	1,193	716	545	495
Total Operating Expenses	189	355	603	-344	557	604	483	563	514	475	371
Selling, General & Admin Expense	58	197	407	415	358	343	356	469	373	301	304
Research & Development Expense	96	99	114	126	126	118	75	77	74	90	105
Amortization Expense	11	28	64	71	68	65	56	50	88	86	83
Other Special Charges / (Income)	24	5.05	17	-3.42	-17	-15	-3.99	-33	-20	-1.04	-121
Total Other Income / (Expense), net	-25	-40	-0.27	4.52	-6.07	-31	-9.03	-33	-165	-27	142
Interest Expense	12	8.42	7.43	6.60	12	22	22	19	12	14	47
Interest & Investment Income	0.77	0.26	0.48	0.61	1.24	1.71	0.15	0.03	1.98	3.98	8.43
Other Income / (Expense), net	-14	-31	6.68	11	4.58	-11	13	-14	-155	-18	181
Income Tax Expense	0.02	-114	-56	19	-39	7.06	18	15	-63	4.44	43
Other Gains / (Losses), net	-3.59	-7.11	-7.65	-14	-14	-2.90	-0.48	-0.63	-0.38	-0.11	-0.02
Basic Earnings per Share	($0.41)	($0.06)	($0.09)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)
Weighted Average Basic Shares Outstanding	422.01M	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	648.08M	719.06M	751.77M	694.02M
Weighted Average Diluted Shares Outstanding	422.01M	488.07M	555.61M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M
Weighted Average Basic & Diluted Shares Outstanding	422.01M	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M

This table shows OPKO Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-85	-18	-20	-84	-66	-82	-10	25	14	-68	-148
Consolidated Net Income / (Loss)	-85	-18	-20	-84	-66	-82	-10	25	14	-68	-148
Net Income / (Loss) Continuing Operations	-85	-18	-20	-84	-66	-82	-10	25	14	-68	-148
Total Pre-Tax Income	-102	-17	-16	-78	-72	-83	-11	48	35	-73	-163
Total Operating Income	-55	-31	7.03	-64	-69	-71	-62	14	-33	-67	-60
Total Gross Profit	56	99	126	48	45	42	52	40	85	43	49
Total Revenue	185	238	265	179	182	174	182	174	184	150	157
Operating Revenue	185	238	265	179	182	174	182	174	184	150	157
Total Cost of Revenue	129	138	139	131	137	132	131	134	99	107	107
Operating Cost of Revenue	129	138	139	131	137	132	131	134	99	107	107
Total Operating Expenses	111	130	119	112	114	114	113	26	118	110	109
Selling, General & Admin Expense	74	76	80	72	73	70	69	98	67	59	60
Research & Development Expense	20	33	18	19	19	22	24	29	30	31	30
Amortization Expense	22	21	22	22	21	21	20	20	20	20	19
Total Other Income / (Expense), net	-47	14	-23	-14	-3.45	-12	51	34	68	-6.21	-103
Interest Expense	3.30	3.39	3.28	3.38	3.45	7.69	8.18	17	14	15	70
Interest & Investment Income	1.14	1.03	1.08	0.97	0.91	0.81	0.39	2.93	4.29	4.68	3.29
Other Income / (Expense), net	-45	16	-21	-12	-0.90	-4.84	59	49	78	4.58	-35
Income Tax Expense	-17	1.23	3.15	6.08	-6.02	-1.35	-0.28	24	21	-5.77	-14
Other Gains / (Losses), net	-0.02	-0.04	-0.04	-0.02	-0.01	-0.00	-0.00	-0.00	-0.01	-0.01	0.00
Basic Earnings per Share	($0.13)	($0.02)	($0.03)	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01	($0.10)	($0.19)
Weighted Average Basic Shares Outstanding	719.06M	751.51M	751.73M	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M	671.58M	788.01M
Diluted Earnings per Share	-	-	-	($0.11)	-	-	($0.01)	$0.03	-	-	($0.19)
Weighted Average Diluted Shares Outstanding	772.65M	772.65M	773.06M	751.53M	696.99M	696.99M	697.21M	998.36M	671.55M	793.05M	788.01M
Weighted Average Basic & Diluted Shares Outstanding	772.65M	772.65M	773.06M	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M	793.05M	793.78M

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-89	97	-25	-77	4.97	-11	-13	62	18	-57	350
Net Cash From Operating Activities	-90	164	32	-92	-109	-173	39	38	-95	-28	-183
Net Cash From Continuing Operating Activities	-90	164	32	-92	-109	-173	39	38	-95	-28	-183
Net Income / (Loss) Continuing Operations	-175	-31	-48	-305	-153	-315	31	-30	-328	-189	-53
Consolidated Net Income / (Loss)	-175	-31	-48	-305	-153	-315	31	-30	-328	-189	-53
Depreciation Expense	15	42	97	102	97	94	85	79	109	105	98
Amortization Expense	2.01	1.21	0.24	0.22	0.19	1.00	0.85	0.79	1.16	1.22	1.97
Non-Cash Adjustments To Reconcile Net Income	45	66	1.61	-9.30	57	58	0.07	-13	159	32	-273
Changes in Operating Assets and Liabilities, net	22	86	-18	120	-110	-9.96	-77	1.54	-35	22	43
Net Cash From Investing Activities	-5.68	-99	-21	-47	-26	-13	-18	36	91	-18	352
Net Cash From Continuing Investing Activities	-5.68	-99	-21	-47	-26	-13	-18	36	91	-18	352
Purchase of Property, Plant & Equipment	-4.73	-11	-19	-47	-28	-13	-34	-32	-25	-16	-25
Acquisitions	-1.68	-84	-5.00	-	-	0.00	0.00	-4.00	-1.76	0.00	0.00
Purchase of Investments	-0.59	-4.38	-30	-9.63	-1.00	-1.20	0.00	-2.00	0.00	-5.00	0.00
Sale of Property, Plant & Equipment	0.00	0.00	1.40	7.27	1.22	0.67	0.25	66	1.95	2.71	0.24
Divestitures	-	-	16	-	-	-	-	-	0.00	0.00	210
Sale and/or Maturity of Investments	0.00	0.00	16	2.21	1.52	0.00	15	8.08	115	0.36	167
Net Cash From Financing Activities	7.26	33	-35	61	141	175	-35	-10	23	-11	184
Net Cash From Continuing Financing Activities	7.26	33	-35	61	141	175	-35	-10	23	-11	184
Repayment of Debt	-28	-254	-66	-34	-35	-396	-1,144	-1,696	-1,036	-683	-665
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-90
Issuance of Debt	26	261	22	92	82	495	1,108	1,685	1,060	672	939
Other Financing Activities, net	-6.44	-	-	2.13	1.17	-0.00	0.76	1.08	-0.77	-0.27	-0.21
Effect of Exchange Rate Changes	-0.10	-1.12	-1.01	0.47	-	-0.48	0.69	-1.44	-0.34	0.39	-3.16
Cash Interest Paid	6.28	4.57	2.89	1.31	2.08	12	11	8.52	7.42	8.14	21
Cash Income Taxes Paid	0.95	4.88	-27	5.42	-1.41	2.67	-0.90	5.97	8.04	3.71	10

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	-28	-42	-2.72	31	-43	-20	-35	379	26	4.06	-168
Net Cash From Operating Activities	-32	-23	-0.37	33	-38	-36	-26	-77	-44	-35	-83
Net Cash From Continuing Operating Activities	-32	-23	-0.37	33	-38	-36	-26	-77	-44	-35	-83
Net Income / (Loss) Continuing Operations	-85	-18	-20	-84	-66	-82	-10	25	14	-68	-148
Consolidated Net Income / (Loss)	-85	-18	-20	-84	-66	-82	-10	25	14	-68	-148
Depreciation Expense	26	26	27	26	26	26	24	24	24	23	23
Amortization Expense	0.30	0.30	0.30	0.31	0.31	0.52	0.43	0.38	0.65	0.43	4.53
Non-Cash Adjustments To Reconcile Net Income	43	-4.21	18	12	6.80	9.62	-50	-120	-111	5.23	90
Changes in Operating Assets and Liabilities, net	-16	-27	-26	79	-4.91	10	8.81	-6.33	28	3.92	-52
Net Cash From Investing Activities	-7.87	-7.72	-5.49	-3.57	-1.42	-4.40	-7.16	248	116	41	-2.83
Net Cash From Continuing Investing Activities	-7.87	-7.72	-5.49	-3.57	-1.42	-4.40	-7.16	248	116	41	-2.83
Purchase of Property, Plant & Equipment	-6.34	-3.04	-6.01	-4.20	-3.02	-4.44	-7.22	-7.94	-5.41	-3.19	-3.28
Purchase of Investments	-	-5.00	-	-	-	0.00	-	-1.45	1.45	-8.00	0.34
Sale of Property, Plant & Equipment	0.45	-	-	-	1.60	0.05	-	-	0.07	0.07	0.11
Net Cash From Financing Activities	10	-13	3.46	2.11	-3.75	21	-2.12	206	-40	-4.02	-79
Net Cash From Continuing Financing Activities	10	-13	3.46	2.11	-3.75	21	-2.12	206	-40	-4.02	-79
Repayment of Debt	-156	-178	-173	-171	-160	-323	-156	-151	-35	-9.72	-9.67
Repurchase of Common Equity	-	0.00	-	-	-	-50	-	-24	-16	0.00	-18
Issuance of Debt	166	165	177	173	156	394	154	381	11	5.61	11
Other Financing Activities, net	-0.09	-	-	0.03	0.00	0.00	-	-	-	0.09	-62
Cash Interest Paid	0.40	3.83	0.37	6.54	-2.61	3.13	0.39	9.47	7.90	14	6.31
Cash Income Taxes Paid	3.57	0.48	0.21	-1.51	4.54	1.06	0.51	2.23	6.21	2.06	18

This table presents OPKO Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	-	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200
Total Current Assets	-	454	484	349	318	324	523	823	395	309	662
Restricted Cash	-	-	-	-	-	-	-	-	-	96	432
Accounts Receivable	-	194	220	166	144	135	286	260	127	123	118
Inventories, net	-	40	47	49	42	53	132	87	74	66	57
Prepaid Expenses	-	27	47	43	35	51	32	27	40	25	55
Other Current Assets	-	-	-	-	-	-	0.00	315	-	-	0.00
Plant, Property, & Equipment, net	-	132	123	147	145	0.00	141	80	83	75	70
Total Noncurrent Assets	-	2,213	2,160	2,095	1,989	1,985	1,809	1,497	1,690	1,627	1,468
Long-Term Investments	-	35	41	41	31	21	16	11	28	16	55
Goodwill	-	743	705	717	700	672	681	521	596	598	529
Intangible Assets	-	1,430	1,409	1,331	1,250	529	1,065	912	1,019	935	812
Other Noncurrent Operating Assets	-	4.84	5.76	5.62	7.22	764	48	54	47	77	73
Total Liabilities & Shareholders' Equity	-	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200
Total Liabilities	-	819	675	746	660	695	802	715	606	622	835
Total Current Liabilities	-	252	263	312	288	249	375	330	213	200	193
Short-Term Debt	-	11	12	12	37	9.62	-	15	37	27	15
Accounts Payable	-	73	53	74	47	63	101	82	67	70	47
Accrued Expenses	-	168	198	226	204	165	241	193	98	90	118
Other Current Liabilities	-	-	-	-	-	12	34	12	12	13	13
Total Noncurrent Liabilities	-	567	412	434	371	445	426	385	392	422	642
Long-Term Debt	-	49	44	29	57	211	222	188	210	214	419
Noncurrent Deferred & Payable Income Tax Liabilities	-	226	165	149	115	119	137	148	126	127	141
Other Noncurrent Operating Liabilities	-	292	202	256	199	115	67	48	55	81	82
Total Equity & Noncontrolling Interests	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Total Preferred & Common Equity	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Total Common Equity	-	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365
Common Stock	-	2,711	2,851	2,895	3,010	3,150	3,159	3,229	3,430	3,441	3,488
Retained Earnings	-	-705	-730	-1,049	-1,197	-1,511	-1,482	-1,512	-1,823	-2,012	-2,065
Treasury Stock	-	-3.65	-1.91	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79
Accumulated Other Comprehensive Income / (Loss)	-	-23	-27	-0.53	-20	-22	-4.23	-30	-43	-38	-56

This table presents OPKO Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	2,370	2,225	2,170	2,159	2,057	1,974	1,980	2,256	2,128	1,973
Total Current Assets	495	414	406	434	357	391	358	630	738	583
Cash & Equivalents	210	181	111	108	139	76	41	406	436	272
Accounts Receivable	158	123	121	211	117	111	105	107	96	99
Inventories, net	83	71	75	74	69	59	60	59	64	66
Prepaid Expenses	43	39	99	41	32	25	32	57	54	59
Other Current Assets	0.00	0.00	-	-	-	-	-	-	87	87
Plant, Property, & Equipment, net	79	0.00	81	79	78	64	67	72	71	75
Total Noncurrent Assets	1,796	1,811	1,487	1,646	1,621	1,519	1,555	1,554	1,320	1,315
Long-Term Investments	109	78	41	28	19	41	101	101	13	13
Goodwill	579	573	597	597	594	531	530	536	477	484
Intangible Assets	1,057	835	804	782	953	875	854	836	569	751
Other Noncurrent Operating Assets	51	324	45	239	54	72	69	81	262	67
Total Liabilities & Shareholders' Equity	2,370	2,225	2,170	2,159	2,057	1,974	1,980	2,256	2,128	1,973
Total Liabilities	651	596	618	624	612	721	585	853	817	676
Total Current Liabilities	215	267	222	226	201	204	220	212	296	171
Short-Term Debt	19	94	24	29	30	23	22	13	113	14
Accounts Payable	56	50	81	88	67	71	82	63	59	57
Accrued Expenses	128	112	106	99	92	89	95	123	113	91
Other Current Liabilities	12	12	11	11	11	12	12	13	9.89	9.92
Total Noncurrent Liabilities	435	328	395	397	412	517	365	641	521	505
Long-Term Debt	211	142	211	212	213	323	176	424	323	326
Noncurrent Deferred & Payable Income Tax Liabilities	177	135	130	133	138	122	119	128	129	113
Other Noncurrent Operating Liabilities	47	52	54	52	60	72	70	89	68	65
Total Equity & Noncontrolling Interests	1,719	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297
Total Preferred & Common Equity	1,719	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297
Total Common Equity	1,719	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297
Common Stock	3,421	3,427	3,432	3,435	3,438	3,393	3,548	3,524	3,491	3,604
Retained Earnings	-1,652	-1,738	-1,841	-1,861	-1,945	-2,094	-2,104	-2,079	-2,133	-2,281
Treasury Stock	-	-	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79
Accumulated Other Comprehensive Income / (Loss)	-49	-58	-38	-37	-46	-45	-47	-40	-45	-25

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	615.46%	439.49%	127.25%	56.49%	-43.37%	-8.92%	59.15%	23.64%	-43.42%	-14.01%	-17.41%
EBITDA Growth	-421.55%	39.43%	108.04%	-2,456.56%	57.77%	-175.53%	182.31%	-46.18%	-422.11%	74.86%	288.68%
EBIT Growth	-483.48%	18.62%	30.78%	-195.91%	37.35%	-71.14%	124.71%	-93.15%	-8,002.34%	54.18%	116.41%
NOPAT Growth	-843.30%	32.46%	1.96%	-186.32%	38.07%	-60.08%	119.20%	-64.36%	-1,306.68%	30.60%	3.16%
Net Income Growth	-52.65%	82.00%	-53.87%	3,084.90%	-110.60%	-105.78%	109.71%	-198.55%	-989.49%	42.49%	71.82%
EPS Growth	0.00%	85.37%	-66.67%	0.00%	0.00%	-96.30%	109.43%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	281.48%	-80.46%	-387.34%	-18.53%	-58.07%	122.88%	-2.89%	-348.30%	70.38%	-550.74%
Free Cash Flow Firm Growth	209.01%	-339.41%	89.72%	95.62%	-1,384.41%	-29.74%	75.83%	222.52%	-131.59%	90.48%	6,944.94%
Invested Capital Growth	-100.00%	0.00%	6.94%	-9.55%	0.33%	-1.64%	4.41%	-1.95%	-8.08%	-6.67%	-13.55%
Revenue Q/Q Growth	3,554.73%	103.95%	-8.58%	79.11%	-42.16%	0.28%	23.20%	-5.00%	-17.70%	-0.40%	0.24%
EBITDA Q/Q Growth	-159.19%	35.96%	-85.49%	-111.08%	42.98%	-3.00%	3,140.41%	-57.43%	-12.94%	30.25%	727.88%
EBIT Q/Q Growth	-189.96%	18.79%	-90.64%	-49.08%	24.35%	-1.65%	183.79%	-95.90%	-11.23%	14.68%	133.27%
NOPAT Q/Q Growth	-71.44%	19.93%	-213.38%	-43.62%	28.31%	-8.92%	150.54%	-87.16%	3.34%	-9.62%	19.10%
Net Income Q/Q Growth	-28.72%	63.66%	-392.50%	1,261.53%	-110.53%	-13.02%	126.82%	-139.70%	-3.61%	9.03%	60.20%
EPS Q/Q Growth	0.00%	80.00%	-225.00%	0.00%	0.00%	-10.42%	127.78%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	10.37%	521.05%	-44.14%	-50.81%	-7.06%	196.71%	-51.00%	-37.53%	-31.01%	-3.45%
Free Cash Flow Firm Q/Q Growth	1,913.87%	-77.14%	-21.01%	94.45%	-431.19%	-0.90%	59.18%	-52.51%	-142.83%	93.96%	53.85%
Invested Capital Q/Q Growth	-100.00%	-1.81%	-2.31%	-12.42%	-2.10%	-2.92%	0.03%	-1.95%	1.32%	-0.73%	-1.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	47.33%	52.16%	45.28%	64.54%	38.94%	36.53%	37.69%	32.77%	28.70%	36.84%	30.64%
EBITDA Margin	-156.45%	-17.57%	0.62%	-9.36%	-6.98%	-21.11%	10.91%	4.75%	-27.05%	-7.91%	18.06%
Operating Margin	-159.97%	-20.03%	-8.64%	-15.81%	-17.29%	-30.38%	4.02%	1.06%	-22.53%	-18.18%	-21.32%
EBIT Margin	-175.03%	-26.40%	-8.04%	-15.21%	-16.83%	-31.62%	4.91%	0.27%	-37.99%	-20.24%	4.02%
Profit (Net Income) Margin	-191.60%	-6.39%	-4.33%	82.54%	-15.45%	-34.92%	2.13%	-1.70%	-32.70%	-21.87%	-7.46%
Tax Burden Percent	102.11%	22.77%	49.95%	-530.83%	86.33%	103.27%	62.83%	214.92%	83.88%	102.47%	513.65%
Interest Burden Percent	107.20%	106.29%	107.74%	102.25%	106.39%	106.95%	69.09%	-290.55%	102.64%	105.45%	-36.13%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	36.19%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-23.00%	-7.61%	-3.61%	-10.49%	-6.83%	-11.00%	2.08%	0.73%	-9.32%	-6.99%	-7.52%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,008.77%	-52.30%	-15.55%	-1,345.46%	46.71%	-312.54%	-2.94%	-38.71%	-234.47%	-87.82%	130.12%
Return on Net Nonoperating Assets (RNNOA)	-17.01%	4.43%	1.23%	83.85%	-1.59%	-7.49%	-0.22%	-2.53%	-10.91%	-5.81%	3.65%
Return on Equity (ROE)	-40.01%	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%
Cash Return on Invested Capital (CROIC)	177.00%	-207.61%	-10.31%	-0.46%	-7.15%	-9.34%	-2.23%	2.70%	-0.90%	-0.09%	7.01%
Operating Return on Assets (OROA)	-22.93%	-9.28%	-3.23%	-9.93%	-6.61%	-11.98%	2.95%	0.20%	-16.70%	-8.37%	1.36%
Return on Assets (ROA)	-25.10%	-2.25%	-1.74%	53.90%	-6.07%	-13.23%	1.28%	-1.24%	-14.38%	-9.04%	-2.53%
Return on Common Equity (ROCE)	-40.17%	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-1.59%	-2.31%	78.30%	-8.54%	-19.50%	1.83%	-1.79%	-21.03%	-13.59%	-3.90%
Net Operating Profit after Tax (NOPAT)	-102	-69	-68	-194	-120	-192	37	13	-158	-110	-106
NOPAT Margin	-111.98%	-14.02%	-6.05%	-11.07%	-12.10%	-21.27%	2.57%	0.74%	-15.77%	-12.73%	-14.93%
Net Nonoperating Expense Percent (NNEP)	985.77%	44.69%	11.94%	1,334.97%	-53.53%	301.54%	5.02%	39.44%	225.15%	80.83%	-137.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-8.76%	-6.74%	-5.91%
Cost of Revenue to Revenue	52.67%	47.84%	54.72%	35.46%	61.06%	63.47%	62.31%	67.23%	71.30%	63.16%	69.36%
SG&A Expenses to Revenue	63.57%	39.98%	36.45%	23.71%	36.19%	38.06%	24.77%	26.42%	37.11%	34.81%	42.66%
R&D to Revenue	104.91%	20.23%	10.19%	7.23%	12.68%	13.07%	5.25%	4.33%	7.36%	10.38%	14.75%
Operating Expenses to Revenue	207.28%	72.19%	53.92%	-19.65%	56.23%	66.91%	33.67%	31.71%	51.23%	55.03%	51.96%
Earnings before Interest and Taxes (EBIT)	-160	-130	-90	-266	-167	-285	70	4.83	-381	-175	29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-143	-86	6.94	-164	-69	-190	157	84	-272	-68	129
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.77	2.48	1.49	0.94	0.61	1.58	1.94	0.62	0.84	0.73
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	2.36	0.00	12.97	0.00	0.00	40.81
Price to Revenue (P/Rev)	47.58	11.14	4.64	1.57	1.70	1.08	1.84	1.85	0.96	1.35	1.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	86.53	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	2.93	2.60	1.51	0.94	0.63	1.54	1.88	0.63	0.85	0.72
Enterprise Value to Revenue (EV/Rev)	47.58	10.80	4.50	1.52	1.67	1.21	1.94	1.88	1.03	1.50	1.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	724.60	0.00	0.00	0.00	17.75	39.54	0.00	0.00	7.38
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	39.46	690.79	0.00	0.00	33.16
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	75.50	254.05	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	32.37	156.99	0.00	0.00	0.00	70.44	86.98	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.52	0.00	0.00	0.00	0.00	0.00	0.00	69.11	0.00	0.00	9.58
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.03	0.03	0.02	0.05	0.14	0.13	0.12	0.16	0.17	0.32
Long-Term Debt to Equity	0.00	0.02	0.02	0.02	0.03	0.13	0.13	0.11	0.13	0.15	0.31
Financial Leverage	0.02	-0.08	-0.08	-0.06	-0.03	0.02	0.08	0.07	0.05	0.07	0.03
Leverage Ratio	1.59	1.41	1.37	1.36	1.39	1.40	1.46	1.45	1.41	1.42	1.53
Compound Leverage Factor	1.71	1.50	1.47	1.39	1.48	1.49	1.01	-4.22	1.44	1.49	-0.55
Debt to Total Capital	0.00%	2.96%	2.59%	2.18%	5.02%	12.03%	11.72%	10.73%	13.65%	14.82%	24.13%
Short-Term Debt to Total Capital	0.00%	0.56%	0.56%	0.63%	1.98%	0.52%	0.00%	0.78%	2.02%	1.67%	0.83%
Long-Term Debt to Total Capital	0.00%	2.40%	2.04%	1.55%	3.04%	11.51%	11.72%	9.96%	11.63%	13.14%	23.29%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	97.04%	97.41%	97.82%	94.98%	87.97%	88.28%	89.27%	86.35%	85.18%	75.87%
Debt to EBITDA	0.00	-0.70	8.02	-0.25	-1.37	-1.16	1.42	2.40	-0.91	-3.54	3.37
Net Debt to EBITDA	0.00	1.94	-22.21	0.56	0.48	-0.60	0.86	0.68	-0.24	-1.90	-0.41
Long-Term Debt to EBITDA	0.00	-0.57	6.29	-0.18	-0.83	-1.11	1.42	2.23	-0.77	-3.14	3.25
Debt to NOPAT	0.00	-0.88	-0.82	-0.21	-0.79	-1.15	6.03	15.44	-1.56	-2.20	-4.08
Net Debt to NOPAT	0.00	2.44	2.28	0.47	0.28	-0.60	3.64	4.36	-0.41	-1.18	0.49
Long-Term Debt to NOPAT	0.00	-0.71	-0.65	-0.15	-0.48	-1.10	6.03	14.32	-1.33	-1.95	-3.94
Altman Z-Score	0.00	3.77	4.63	1.99	1.04	-0.05	1.89	2.86	-0.24	-0.07	0.03
Noncontrolling Interest Sharing Ratio	-0.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	1.80	1.84	1.12	1.10	1.30	1.39	2.49	1.85	1.55	3.43
Quick Ratio	0.00	1.54	1.48	0.82	0.83	0.88	0.95	1.20	1.31	0.62	2.85
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	786	-1,881	-193	-8.46	-126	-163	-39	48	-15	-1.45	99
Operating Cash Flow to CapEx	-1,909.15%	1,512.30%	186.90%	-234.58%	-409.77%	-1,429.35%	118.06%	0.00%	-420.69%	-207.91%	-740.83%
Free Cash Flow to Firm to Interest Expense	64.07	-223.41	-26.01	-1.28	-10.56	-7.57	-1.80	2.56	-1.26	-0.11	2.09
Operating Cash Flow to Interest Expense	-7.37	19.48	4.31	-13.95	-9.18	-8.02	1.80	2.03	-7.90	-2.09	-3.87
Operating Cash Flow Less CapEx to Interest Expense	-7.76	18.19	2.01	-19.90	-11.42	-8.58	0.28	3.82	-9.77	-3.09	-4.39
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.35	0.40	0.65	0.39	0.38	0.60	0.73	0.44	0.41	0.34
Accounts Receivable Turnover	0.00	0.00	5.40	9.07	6.40	6.48	6.82	6.50	5.19	6.89	5.91
Inventory Turnover	0.00	0.00	14.07	12.84	13.20	11.96	9.63	10.90	8.92	7.80	8.08
Fixed Asset Turnover	0.00	0.00	8.78	12.98	6.80	0.00	0.00	16.11	12.35	10.91	9.80
Accounts Payable Turnover	0.00	0.00	9.71	9.71	9.94	10.42	10.95	13.05	9.61	7.98	8.47
Days Sales Outstanding (DSO)	0.00	0.00	67.64	40.26	57.02	56.36	53.52	56.14	70.32	52.98	61.78
Days Inventory Outstanding (DIO)	0.00	0.00	25.94	28.42	27.66	30.52	37.91	33.47	40.93	46.77	45.20
Days Payable Outstanding (DPO)	0.00	0.00	37.57	37.57	36.73	35.04	33.35	27.98	37.99	45.73	43.08
Cash Conversion Cycle (CCC)	0.00	0.00	56.00	31.11	47.95	51.83	58.08	61.64	73.26	54.02	63.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,812	1,938	1,753	1,758	1,729	1,806	1,770	1,627	1,519	1,313
Invested Capital Turnover	0.21	0.54	0.60	0.95	0.56	0.52	0.81	0.99	0.59	0.55	0.50
Increase / (Decrease) in Invested Capital	-888	1,812	126	-185	5.73	-29	76	-35	-143	-108	-206
Enterprise Value (EV)	4,337	5,310	5,031	2,650	1,652	1,093	2,781	3,334	1,032	1,297	951
Market Capitalization	4,337	5,477	5,185	2,741	1,685	978	2,647	3,277	966	1,167	1,003
Book Value per Share	$0.00	$3.63	$3.75	$3.30	$3.20	$2.43	$2.49	$2.47	$2.02	$1.80	$2.00
Tangible Book Value per Share	$0.00	($0.36)	($0.04)	($0.37)	($0.28)	$0.62	($0.11)	$0.37	($0.07)	($0.19)	$0.04
Total Capital	0.00	2,040	2,147	1,885	1,886	1,836	1,894	1,888	1,809	1,631	1,800
Total Debt	0.00	60	56	41	95	221	222	203	247	242	434
Total Long-Term Debt	0.00	49	44	29	57	211	222	188	210	214	419
Net Debt	0.00	-168	-154	-91	-33	115	134	57	66	130	-52
Capital Expenditures (CapEx)	4.73	11	17	39	27	12	33	-34	23	14	25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	20	64	-43	-30	-0.91	75	373	64	41	52
Debt-free Net Working Capital (DFNWC)	0.00	214	232	49	67	85	148	508	218	137	484
Net Working Capital (NWC)	0.00	202	220	37	29	75	148	493	181	109	469
Net Nonoperating Expense (NNE)	73	-38	-19	-1,637	33	123	6.24	43	170	79	-53
Net Nonoperating Obligations (NNO)	0.00	-168	-154	-91	-33	115	134	85	66	130	-52
Total Depreciation and Amortization (D&A)	17	43	97	102	98	95	86	80	110	107	100
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	4.07%	5.69%	-2.44%	-2.99%	-0.10%	5.26%	21.02%	6.42%	4.73%	7.30%
Debt-free Net Working Capital to Revenue	0.00%	43.44%	20.79%	2.79%	6.75%	9.37%	10.29%	28.61%	21.67%	15.83%	67.87%
Net Working Capital to Revenue	0.00%	41.11%	19.71%	2.11%	2.97%	8.31%	10.29%	27.78%	18.03%	12.67%	65.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)
Adjusted Weighted Average Basic Shares Outstanding	451.63M	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	751.77M	694.02M
Adjusted Diluted Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	451.63M	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	696.99M	671.55M
Adjusted Basic & Diluted Earnings per Share	($0.41)	($0.06)	($0.05)	($0.55)	$0.00	($0.53)	$0.05	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	422.01M	488.07M	550.85M	559.16M	615.60M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M
Normalized Net Operating Profit after Tax (NOPAT)	-85	-65	-56	-187	-116	-138	34	-10	-172	-111	-191
Normalized NOPAT Margin	-93.21%	-13.30%	-4.99%	-10.67%	-11.75%	-15.25%	2.39%	-0.57%	-17.16%	-12.81%	-26.85%
Pre Tax Income Margin	-187.63%	-28.06%	-8.66%	-15.55%	-17.90%	-33.81%	3.39%	-0.79%	-38.99%	-21.35%	-1.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-13.01	-15.42	-12.10	-40.29	-14.01	-13.25	3.21	0.26	-31.64	-12.94	0.60
NOPAT to Interest Expense	-8.32	-8.19	-9.10	-29.32	-10.08	-8.92	1.68	0.70	-13.14	-8.14	-2.24
EBIT Less CapEx to Interest Expense	-13.40	-16.71	-14.40	-46.23	-16.25	-13.81	1.69	2.05	-33.52	-13.95	0.08
NOPAT Less CapEx to Interest Expense	-8.71	-9.48	-11.40	-35.26	-12.32	-9.48	0.15	2.49	-15.01	-9.14	-2.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	1.54%	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	1.54%	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-53.82%	-27.84%	-14.35%	-0.64%	-1.85%	-26.89%	-31.36%	-2.78%	0.95%	-13.66%	-13.93%
EBITDA Growth	-73.87%	126.37%	122.86%	49.32%	40.42%	-512.78%	72.92%	277.16%	259.49%	22.61%	-411.78%
EBIT Growth	-62.61%	80.22%	82.91%	38.75%	30.07%	-421.39%	80.39%	182.74%	164.24%	17.98%	-3,316.10%
NOPAT Growth	12.39%	57.76%	165.42%	26.66%	-24.92%	-133.61%	-977.86%	116.21%	72.49%	6.02%	2.74%
Net Income Growth	-15.53%	67.05%	80.68%	1.88%	22.00%	-348.00%	47.53%	129.47%	121.10%	17.38%	-1,340.48%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	127.27%	0.00%	0.00%	-1,800.00%
Operating Cash Flow Growth	-460.34%	-14.06%	96.82%	202.71%	-21.11%	-57.05%	-7,142.47%	-332.80%	-15.97%	2.85%	-215.57%
Free Cash Flow Firm Growth	1,256.17%	929.17%	-102.35%	-77.42%	-42.43%	-93.70%	4,812.18%	552.94%	220.04%	35.18%	-121.01%
Invested Capital Growth	-8.08%	-18.14%	0.64%	-4.75%	-6.67%	-4.77%	-18.27%	-12.82%	-13.55%	-5.27%	0.89%
Revenue Q/Q Growth	3.11%	28.18%	11.72%	-32.71%	1.85%	-4.52%	4.89%	-4.70%	5.76%	-18.34%	4.57%
EBITDA Q/Q Growth	24.73%	116.52%	4.07%	-491.55%	11.52%	-14.48%	143.60%	301.16%	-20.34%	-155.55%	-75.64%
EBIT Q/Q Growth	19.35%	85.37%	2.64%	-433.08%	7.92%	-9.10%	96.34%	2,348.69%	-28.51%	-239.30%	-52.55%
NOPAT Q/Q Growth	37.06%	44.65%	122.96%	-1,016.83%	-7.20%	-3.52%	13.71%	116.93%	-281.94%	-253.59%	10.70%
Net Income Q/Q Growth	1.00%	78.57%	-7.52%	-330.11%	21.30%	-23.09%	87.41%	341.53%	-43.64%	-582.02%	-119.55%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	1.91%	28.38%	98.39%	9,170.96%	-215.66%	7.12%	25.67%	-191.58%	42.39%	22.19%	-141.42%
Free Cash Flow Firm Q/Q Growth	-24.29%	185.04%	-101.83%	672.14%	93.00%	-68.83%	1,269.08%	-20.72%	-5.40%	-86.83%	-312.80%
Invested Capital Q/Q Growth	1.32%	-11.48%	13.89%	-6.74%	-0.73%	-9.69%	-2.26%	-0.51%	-1.55%	-1.05%	4.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.21%	41.78%	47.65%	26.70%	24.58%	24.22%	28.35%	23.11%	46.10%	28.42%	31.51%
EBITDA Margin	-39.53%	5.10%	4.75%	-27.62%	-24.00%	-28.77%	11.96%	50.33%	37.91%	-25.79%	-43.32%
Operating Margin	-29.82%	-12.88%	2.65%	-36.06%	-37.96%	-41.15%	-33.85%	8.19%	-18.05%	-44.79%	-38.25%
EBIT Margin	-53.97%	-6.16%	-5.37%	-42.53%	-38.45%	-43.94%	-1.53%	36.20%	24.47%	-41.74%	-60.89%
Profit (Net Income) Margin	-45.99%	-7.69%	-7.40%	-47.30%	-36.55%	-47.12%	-5.66%	14.33%	7.64%	-45.09%	-94.66%
Tax Burden Percent	83.41%	107.47%	119.39%	107.78%	91.71%	98.38%	97.36%	51.40%	40.09%	92.15%	91.34%
Interest Burden Percent	102.16%	116.13%	115.44%	103.18%	103.64%	109.01%	378.68%	77.04%	77.86%	117.23%	170.21%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	48.59%	59.87%	0.00%	0.00%
Return on Invested Capital (ROIC)	-12.34%	-5.14%	0.98%	-13.96%	-14.58%	-16.38%	-11.39%	2.09%	-3.65%	-16.19%	-13.20%
ROIC Less NNEP Spread (ROIC-NNEP)	-73.97%	13.75%	-297.41%	-139.89%	-33.17%	-863.97%	118.68%	224.05%	67.02%	-54.85%	-18,755.16%
Return on Net Nonoperating Assets (RNNOA)	-3.44%	0.14%	-1.50%	-2.85%	-2.20%	-2.31%	2.05%	1.25%	1.88%	-2.28%	-7.91%
Return on Equity (ROE)	-15.78%	-5.00%	-0.52%	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%	-18.46%	-21.12%
Cash Return on Invested Capital (CROIC)	-0.90%	11.88%	-7.77%	-1.53%	-0.09%	-4.96%	7.59%	4.51%	7.01%	-2.33%	-8.48%
Operating Return on Assets (OROA)	-23.73%	-2.51%	-2.06%	-17.23%	-15.89%	-16.96%	-0.53%	11.94%	8.29%	-14.03%	-20.46%
Return on Assets (ROA)	-20.22%	-3.13%	-2.84%	-19.15%	-15.10%	-18.18%	-1.96%	4.73%	2.59%	-15.15%	-31.80%
Return on Common Equity (ROCE)	-15.78%	-5.00%	-0.52%	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%	-18.46%	-21.12%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-18.77%	-13.63%	-14.37%	0.00%	-20.15%	-17.42%	-9.53%	0.00%	-2.97%	0.00%
Net Operating Profit after Tax (NOPAT)	-39	-21	4.92	-45	-48	-50	-43	7.31	-13	-47	-42
NOPAT Margin	-20.87%	-9.01%	1.85%	-25.24%	-26.57%	-28.81%	-23.70%	4.21%	-7.24%	-31.36%	-26.78%
Net Nonoperating Expense Percent (NNEP)	61.63%	-18.90%	298.39%	125.94%	18.58%	847.58%	-130.07%	-221.96%	-70.66%	38.67%	18,741.95%
Return On Investment Capital (ROIC_SIMPLE)	-2.14%	-	-	-	-2.96%	-	-	-	-0.74%	-2.69%	-2.56%
Cost of Revenue to Revenue	69.79%	58.22%	52.35%	73.30%	75.42%	75.78%	71.65%	76.89%	53.90%	71.58%	68.50%
SG&A Expenses to Revenue	39.93%	31.84%	30.06%	40.45%	40.07%	40.40%	37.78%	56.56%	36.50%	39.40%	38.01%
R&D to Revenue	10.54%	13.72%	6.84%	10.88%	10.66%	12.63%	13.22%	16.57%	16.57%	20.57%	19.35%
Operating Expenses to Revenue	60.03%	54.66%	45.01%	62.76%	62.53%	65.37%	62.20%	14.92%	64.15%	73.22%	69.76%
Earnings before Interest and Taxes (EBIT)	-100	-15	-14	-76	-70	-76	-2.80	63	45	-63	-95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-73	12	13	-49	-44	-50	22	87	70	-39	-68
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.62	0.73	1.09	0.86	0.84	0.67	0.62	0.74	0.73	0.85	0.81
Price to Tangible Book Value (P/TBV)	0.00	7.48	10.76	0.00	0.00	0.00	78.49	33.35	40.81	4.18	16.96
Price to Revenue (P/Rev)	0.96	1.24	1.93	1.43	1.35	1.05	1.22	1.46	1.41	1.62	1.58
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.63	0.84	1.09	0.86	0.85	0.78	0.69	0.73	0.72	0.85	0.82
Enterprise Value to Revenue (EV/Rev)	1.03	1.33	2.05	1.53	1.50	1.33	1.29	1.36	1.33	1.60	1.66
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	62.30	7.38	7.87	21.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.16	26.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.38	0.00	0.00	0.00	0.00	8.20	15.02	9.58	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.15	0.16	0.17	0.17	0.28	0.14	0.31	0.32	0.33	0.26
Long-Term Debt to Equity	0.13	0.14	0.14	0.15	0.15	0.26	0.13	0.30	0.31	0.25	0.25
Financial Leverage	0.05	0.01	0.01	0.02	0.07	0.00	0.02	0.01	0.03	0.04	0.00
Leverage Ratio	1.41	1.41	1.39	1.39	1.42	1.48	1.41	1.51	1.53	1.60	1.47
Compound Leverage Factor	1.44	1.64	1.61	1.44	1.47	1.61	5.35	1.17	1.19	1.88	2.50
Debt to Total Capital	13.65%	13.19%	13.57%	14.42%	14.82%	21.65%	12.44%	23.76%	24.13%	24.97%	20.80%
Short-Term Debt to Total Capital	2.02%	1.36%	1.62%	1.78%	1.67%	1.44%	1.40%	0.73%	0.83%	6.49%	0.86%
Long-Term Debt to Total Capital	11.63%	11.82%	11.95%	12.64%	13.14%	20.21%	11.04%	23.04%	23.29%	18.48%	19.94%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.35%	86.81%	86.43%	85.58%	85.18%	78.35%	87.56%	76.24%	75.87%	75.03%	79.20%
Debt to EBITDA	-0.91	-1.10	-1.65	-2.49	-3.54	-2.66	-1.64	28.11	3.37	3.11	6.75
Net Debt to EBITDA	-0.24	-0.39	-0.72	-0.87	-1.90	-1.76	-0.46	-4.47	-0.41	-0.09	1.11
Long-Term Debt to EBITDA	-0.77	-0.99	-1.46	-2.18	-3.14	-2.48	-1.45	27.25	3.25	2.31	6.48
Debt to NOPAT	-1.56	-1.83	-2.07	-2.43	-2.20	-2.50	-1.06	-3.32	-4.08	-4.22	-3.33
Net Debt to NOPAT	-0.41	-0.65	-0.90	-0.85	-1.18	-1.66	-0.30	0.53	0.49	0.12	-0.55
Long-Term Debt to NOPAT	-1.33	-1.64	-1.82	-2.13	-1.95	-2.33	-0.94	-3.22	-3.94	-3.12	-3.19
Altman Z-Score	0.19	0.41	0.90	0.28	0.10	-0.40	-0.15	0.07	0.05	-0.11	-0.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.85	1.83	1.92	1.78	1.55	1.92	1.63	2.97	3.43	2.49	3.41
Quick Ratio	1.31	1.04	1.41	1.28	0.62	0.92	0.66	2.42	2.85	1.80	2.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	104	298	-5.45	31	60	19	257	203	192	25	-54
Operating Cash Flow to CapEx	-537.21%	-745.70%	-6.07%	787.75%	-2,700.56%	-800.50%	-366.29%	-971.14%	-831.63%	-1,105.02%	-2,632.38%
Free Cash Flow to Firm to Interest Expense	31.63	87.79	-1.66	9.21	17.41	2.44	31.37	11.72	13.51	1.64	-0.77
Operating Cash Flow to Interest Expense	-9.58	-6.68	-0.11	9.78	-11.09	-4.63	-3.23	-4.44	-3.12	-2.23	-1.19
Operating Cash Flow Less CapEx to Interest Expense	-11.36	-7.57	-1.95	8.54	-11.50	-5.21	-4.11	-4.90	-3.49	-2.44	-1.23
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.44	0.41	0.38	0.41	0.41	0.39	0.35	0.33	0.34	0.34	0.34
Accounts Receivable Turnover	5.19	5.46	4.70	7.21	6.89	6.87	4.53	6.35	5.91	6.64	6.49
Inventory Turnover	8.92	6.98	7.07	7.66	7.80	7.99	7.92	8.30	8.08	7.63	7.07
Fixed Asset Turnover	12.35	11.21	11.02	0.00	10.91	11.03	9.84	9.46	9.80	10.19	9.37
Accounts Payable Turnover	9.61	6.99	7.71	9.22	7.98	7.10	6.23	8.23	8.47	7.21	6.44
Days Sales Outstanding (DSO)	70.32	66.84	77.66	50.66	52.98	53.15	80.58	57.47	61.78	54.93	56.26
Days Inventory Outstanding (DIO)	40.93	52.27	51.64	47.67	46.77	45.66	46.08	43.97	45.20	47.87	51.62
Days Payable Outstanding (DPO)	37.99	52.24	47.34	39.57	45.73	51.38	58.55	44.36	43.08	50.65	56.69
Cash Conversion Cycle (CCC)	73.26	66.87	81.96	58.75	54.02	47.43	68.11	57.08	63.90	52.16	51.19
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,627	1,440	1,640	1,530	1,519	1,372	1,341	1,334	1,313	1,299	1,353
Invested Capital Turnover	0.59	0.57	0.53	0.55	0.55	0.57	0.48	0.50	0.50	0.52	0.49
Increase / (Decrease) in Invested Capital	-143	-319	10	-76	-108	-69	-300	-196	-206	-72	12
Enterprise Value (EV)	1,032	1,212	1,782	1,322	1,297	1,066	927	970	951	1,102	1,103
Market Capitalization	966	1,128	1,677	1,237	1,167	836	871	1,039	1,003	1,115	1,047
Book Value per Share	$2.02	$2.01	$1.99	$1.87	$1.80	$1.80	$2.00	$2.01	$2.00	$1.95	$1.64
Tangible Book Value per Share	($0.07)	$0.20	$0.20	($0.13)	($0.19)	($0.22)	$0.02	$0.04	$0.04	$0.40	$0.08
Total Capital	1,809	1,788	1,776	1,688	1,631	1,599	1,594	1,841	1,800	1,748	1,637
Total Debt	247	236	241	243	242	346	198	437	434	436	341
Total Long-Term Debt	210	211	212	213	214	323	176	424	419	323	326
Net Debt	66	84	105	85	130	229	56	-70	-52	-12	56
Capital Expenditures (CapEx)	5.89	3.04	6.01	4.20	1.42	4.44	7.22	7.94	5.34	3.13	3.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	64	98	128	48	41	134	120	25	52	119	154
Debt-free Net Working Capital (DFNWC)	218	208	236	187	137	210	161	431	484	555	426
Net Working Capital (NWC)	181	184	207	157	109	187	138	418	469	442	412
Net Nonoperating Expense (NNE)	47	-3.15	25	39	18	32	-33	-18	-27	21	106
Net Nonoperating Obligations (NNO)	66	-111	105	85	130	119	-55	-70	-52	-12	56
Total Depreciation and Amortization (D&A)	27	27	27	27	26	26	25	25	25	24	28
Debt-free, Cash-free Net Working Capital to Revenue	6.42%	10.69%	14.74%	5.56%	4.73%	16.80%	16.77%	3.51%	7.30%	17.28%	23.26%
Debt-free Net Working Capital to Revenue	21.67%	22.83%	27.19%	21.55%	15.83%	26.26%	22.44%	60.64%	67.87%	80.52%	64.18%
Net Working Capital to Revenue	18.03%	20.16%	23.88%	18.07%	12.67%	23.38%	19.32%	58.75%	65.76%	64.08%	62.07%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	($0.02)	($0.03)	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01	($0.10)	($0.19)
Adjusted Weighted Average Basic Shares Outstanding	719.06M	751.51M	751.73M	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M	671.58M	788.01M
Adjusted Diluted Earnings per Share	$0.00	($0.02)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.03	$0.00	$0.00	($0.19)
Adjusted Weighted Average Diluted Shares Outstanding	772.65M	751.51M	773.06M	773.06M	696.99M	696.99M	697.38M	998.36M	671.55M	793.05M	788.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	772.65M	772.65M	773.06M	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M	793.05M	793.78M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-21	4.89	-46	-48	-50	-43	7.31	-108	-47	-42
Normalized NOPAT Margin	-22.32%	-8.97%	1.84%	-25.69%	-26.57%	-28.81%	-23.70%	4.21%	-58.94%	-31.36%	-26.78%
Pre Tax Income Margin	-55.13%	-7.15%	-6.20%	-43.89%	-39.85%	-47.89%	-5.81%	27.89%	19.05%	-48.93%	-103.64%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-30.29	-4.32	-4.35	-22.45	-20.25	-9.93	-0.34	3.62	3.16	-4.05	-1.36
NOPAT to Interest Expense	-11.72	-6.32	1.50	-13.32	-13.99	-6.51	-5.28	0.42	-0.93	-3.04	-0.60
EBIT Less CapEx to Interest Expense	-32.07	-5.21	-6.18	-23.69	-20.66	-10.51	-1.22	3.16	2.78	-4.25	-1.40
NOPAT Less CapEx to Interest Expense	-13.50	-7.21	-0.33	-14.57	-14.40	-7.09	-6.16	-0.04	-1.31	-3.24	-0.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%	-103.13%	-33.01%

Key Financial Trends

OPKO Health (NASDAQ: OPK) Q2 2025 Financial Summary and Key Trends

OPKO Health's recent quarterly financials show significant challenges with profitability but some strength in operational cash flows and asset base. Here's a breakdown of the key points and trends over the last four years:

Despite a net loss of $148.4 million in Q2 2025, the company reported a positive gross profit of approximately $49.4 million, consistent with previous quarters indicating operational revenue generation capability.
Depreciation and amortization expenses are significant but stable, with non-cash adjustments positively affecting the cash flow from operations, showing adjustments for non-cash charges around $89.7 million in Q2 2025.
The company maintains a substantial asset base with total assets around $1.97 billion in Q2 2025, including goodwill and intangible assets valued at approximately $484 million and $751 million respectively, supporting its long-term growth potential.
Cash and equivalents, while having decreased from $435.9 million in Q1 2025 to $271.7 million in Q2 2025, still represent a strong liquidity position relative to prior years.
Total revenue in Q2 2025 was about $156.8 million, somewhat lower compared to revenues over $260 million seen in 2023 Q2, indicating pressure or extensive revenue volatility over time.
OPKO's research & development spend remains high (around $30.3 million in Q2 2025) reflecting continued investment in pipeline and innovation, a sign of long-term strategic focus.
Total operating expenses exceeded gross profit in recent quarters, leading to operating losses (e.g., operating loss of ~$60 million in Q2 2025), showing ongoing operational challenges.
Net income has been consistently negative over the last several quarters and years, with the most recent Q2 2025 loss at $148.4 million and earlier quarters also showing substantial net losses.
Interest expense is considerable and has increased significantly over recent quarters, reaching approximately $70 million in Q2 2025, which weighs heavily on profitability.
Negative cash flow from operations is a concern, with $83.4 million used in operating activities in Q2 2025, reflecting ongoing cash burn despite non-cash income adjustments.

Analysis: While OPKO Health generates revenue and maintains a strong asset base including valuable intangible assets and goodwill, it continues to struggle with profitability, largely due to high operating and interest costs. Persistently negative net income and cash flow from operations suggest that OPKO is still in a phase of investment and development without near-term profitability. The high debt burden marked by significant interest expenses also remains a key risk element. Investors should watch for improvements in operational efficiency, revenue stability, and debt management to assess future upside potential.

08/27/25 03:02 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About OPKO Health's Financials

When does OPKO Health's financial year end?

According to the most recent income statement we have on file, OPKO Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has OPKO Health's net income changed over the last 10 years?

OPKO Health's net income appears to be on a downward trend, with a most recent value of -$53.22 million in 2024, falling from -$174.64 million in 2014. The previous period was -$188.86 million in 2023. Check out OPKO Health's forecast to explore projected trends and price targets.

What is OPKO Health's operating income?

OPKO Health's total operating income in 2024 was -$152.07 million, based on the following breakdown:

Total Gross Profit: $218.51 million
Total Operating Expenses: $370.58 million

How has OPKO Health's revenue changed over the last 10 years?

Over the last 10 years, OPKO Health's total revenue changed from $91.15 million in 2014 to $713.14 million in 2024, a change of 682.4%.

How much debt does OPKO Health have?

OPKO Health's total liabilities were at $834.76 million at the end of 2024, a 34.1% increase from 2023, and a 83,476,400,000.0% increase since 2014.

How has OPKO Health's book value per share changed over the last 10 years?

Over the last 10 years, OPKO Health's book value per share changed from 0.00 in 2014 to 2.00 in 2024, a change of 200.1%.

Related Companies

This page (NASDAQ:OPK) was last updated on 8/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About OPKO Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Financials

Annual Income Statements for OPKO Health

Quarterly Income Statements for OPKO Health

Annual Cash Flow Statements for OPKO Health

Quarterly Cash Flow Statements for OPKO Health

Annual Balance Sheets for OPKO Health

Quarterly Balance Sheets for OPKO Health

Annual Metrics And Ratios for OPKO Health

Quarterly Metrics And Ratios for OPKO Health

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About OPKO Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools